NCT00130806View on ClinicalTrials.gov

An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)

PHASE3TerminatedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MK0478 (muraglitazar)

DRUG

Comparator: placebo

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY